Cell Origin Biotech (hangzhou) Co., Ltd.

This early study tests a new treatment called SY001 for people with advanced ovarian or pancreatic cancer that has not responded to at least one prior therapy. SY001 uses specially engineered immune cells (CAR-macrophages) to target a protein called mesothelin found on cancer cel…